TRAWS PHARMA INC (TRAW) Stock News
NASDAQ:TRAW - Nasdaq - US68232V8845 - Common Stock - Currency: USD
TRAW Latest News, Press Releases and Analysis
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
/PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
/PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws...
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
/PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
/PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without...
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment
/PRNewswire/ -- Expert Systems, a leader in combining human and artificial intelligence to accelerate drug discovery, celebrates a key milestone in the...
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy...
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for...
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to...
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split ...
TRAW Stock Earnings: Traws Pharma Reported Results for Q2 2024
Traws Pharma just reported results for the second quarter of 2024.
TRAW Stock Earnings: Traws Pharma Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Traws Pharma (NASDAQ:TRAW) just reported results for the second quarter of 2024...
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations...
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing...
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Differentiated resistance profile positions Traws’ program as a potential class leader
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update...